



Date: 14.02.2025

To  
The Manager  
Listing Compliance  
Bombay Stock Exchange Limited  
P.J Towers, Dalal Street,  
Mumbai-400 001  
Maharashtra, India  
SCRIP CODE: 543919

To  
The Manager  
Listing Compliance  
National Stock Exchange of India  
Limited (NSE)  
Exchange Plaza, Bandra Kurla Complex,  
Bandra East, Mumbai - 400051  
NSE SYMBOL: MKPL

**Subject: Submission of Integrated Filing (Financial) for the Quarter and Nine Months ended 31st December, 2024**

Dear Sir/Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are submitting herewith the Integrated Filing (Financial) for the Quarter and Nine Months ended 31st December, 2024.

The same will be also available on the website of the Company at [www.mkproteins.in](http://www.mkproteins.in). Please take the above on your records.

Thanking you,

Yours Sincerely,  
FOR M K PROTEINS LIMITED

Neha Aggarwal  
Company Secretary cum Compliance Officer

---

## M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: [www.mkproteins.in](http://www.mkproteins.in) | E: [compliancemkproteins@gmail.com](mailto:compliancemkproteins@gmail.com)

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



## M K PROTEINS

### FORMAT FOR QUARTERLY INTEGRATED FILING (FINANCIAL)

#### **A. FINANCIAL RESULTS**

The financial results are the same as filed by the Company with the stock exchanges, a copy of which is attached herewith as an Annexure.

#### **B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Not Applicable.

#### **C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES**

Not applicable as there are no outstanding default on loans and debt securities as of 31st December 2024.

#### **D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (APPLICABLE ONLY FOR HALF-YEARLY FILINGS i.e., 2ND AND 4TH QUARTER)**

The related party transactions are required to be submitted on a half-yearly basis. Hence, Not Applicable for the quarter ended December 31, 2024.

#### **E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED SEPARATELY) (APPLICABLE ONLY FOR ANNUAL FILING i.e., 4TH QUARTER)**

Not Applicable for the quarter ended December 31, 2024.



H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

**Limited Review Report on Standalone Quarterly and year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

To,  
The Board of Directors,  
M. K. Proteins Limited  
Naraingarh Road, Village Garnala,  
Ambala City (Haryana), India - 134003

Ref : **Limited Review Report of Unaudited Standalone Financial Results for the quarter ended 31<sup>st</sup> December, 2024 and year to date from 1<sup>st</sup> April, 2024 to 31<sup>st</sup> December, 2024**

1. We have reviewed the accompanying statement of unaudited quarterly standalone financial results of **M. K. Proteins Limited** ("the Company") for the quarter ended December 31, 2024 and year to date from 1<sup>st</sup> April, 2024 to 31<sup>st</sup> December, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies [Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI( Listing Obligations and Disclosure Requirements) Regulations,2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Company does not have any subsidiary/associate/joint venture company(ies) as on December 31, 2024

Place: New Delhi

Date: 13<sup>th</sup> February 2025

For KRA & Co.,  
Chartered Accountants  
Firm Registration No. 020266N

  
  
**RAJAT GOYAL**  
(PARTNER)  
Membership No.: 503150  
UDIN: 25503150BMJBVG7932



## M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Gamala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01021

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER 2024

(Rs. In Lacs)

	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED	
	31 12 2024 (UNAUDITED)	30 09 2024 (UNAUDITED)	31 12 2023 (UNAUDITED)	31 12 2024 (UNAUDITED)	31 12 2023 (UNAUDITED)	31 03 2024 (AUDITED)	31 03 2023 (AUDITED)
<b>1. Revenue</b>							
a) Revenue from Operation (Net)	3947.88	3369.01	6886.26	13050.19	15869.82	24557.11	31486.00
b) Other Income	24.56	21.16	0.64	45.72	3.62	44.66	55.35
Sub-Total "1"	3972.44	3390.17	6886.90	13095.91	15873.44	24601.77	31541.35
<b>2. Expenditure</b>							
a) Cost of Material Consumed	2003.69	882.10	5736.72	5445.04	9427.33	20571.80	25574.42
b) Purchase of Stock-in-Trade	1968.15	430.17	598.33	2806.28	2935.66	3294.36	4912.19
c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(472.85)	1638.89	(124.37)	3322.95	1761.99	(2223.11)	(1967.95)
d) Employees Benefits Expenses	63.97	62.28	63.47	192.03	199.54	278.80	177.06
e) Manufacturing, Operating and Other Expenses	205.26	131.92	256.46	506.64	725.94	973.61	1080.47
f) Finance Costs	6.92	3.32	10.71	43.06	66.72	106.49	184.16
g) Depreciation and Amortization Expenses	11.43	7.48	11.74	26.32	33.09	52.85	82.02
Sub-Total "2"	3786.57	3156.16	6553.06	12342.32	15152.27	23054.80	30042.37
<b>3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [ 1 - 2 ]</b>	185.87	234.01	333.84	753.59	721.17	1546.97	1498.98
<b>4 Exceptional Items</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>5 Profit/(Loss) before Extraordinary items and Tax [ 3 - 4 ]</b>	185.87	234.01	333.84	753.59	721.17	1546.97	1498.98
<b>6 Extraordinary Items</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>7 Profit/(Loss) before Tax [ 5 - 6 ]</b>	185.87	234.01	333.84	753.59	721.17	1546.97	1498.98
<b>8 Tax Expenses</b>							
a) Provision for Current Tax	47.40	58.43	83.58	190.32	181.58	417.73	399.52
b) Provision for Deferred Tax Liability/(Adjustment)	0.95	1.10	2.30	3.14	1.38	8.05	6.00
c) Prior Year Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sub-Total "8"	48.35	59.53	85.88	193.46	182.96	425.78	405.52
<b>9 Profit/(Loss) for the Period from continuing operations [ 7 - 8 ]</b>	137.52	174.48	247.96	560.13	538.21	1121.19	1093.46
<b>10 Profit/(Loss) for the period from Discontinuing operations before tax</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>11 Tax expenses of Discontinuing operations</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>12 Profit/(Loss) from Discontinuing operations (After Tax) [10 - 11]</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>13 Profit/(Loss) for the period [9 + 12]</b>	137.52	174.48	247.96	560.13	538.21	1121.19	1093.46
<b>14 Other Comprehensive Income net of taxes</b>							
a) (i) Amount of items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	(0.55)	0.79
(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	(0.14)	0.20
b) (i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sub- Total "14"	0.00	0.00	0.00	0.00	0.00	(0.41)	0.59
<b>15 Total comprehensive Income for the Period [13 + 14]</b>	137.52	174.48	247.96	560.13	538.21	1120.78	1094.05
<b>16 Earnings per share</b>							



a)	Earnings per Equity Share for continuing operations							
	Basic earnings/(Loss) per share from continuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
	Diluted earning/(Loss) per share from continuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
b)	Earnings per Equity Share for discontinuing operations							
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share							
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
17	<b>Details of Equity Share Capital</b>							
	Paid-up Equity Share Capital	3753.72	3753.72	1251.24	3753.72	1251.24	3753.72	1251.24
	Face value of Equity Share Capital	1	1	1	1	1	1	10
18	Other Equity [Reserves]	-	-	-	-	-	2353.84	3755.19

**Note:**

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13<sup>th</sup> February, 2025.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015.
4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
5. As on 31<sup>st</sup> December 2024, the Company does not have any Associate, Subsidiary or Joint Venture Company.

For and on behalf of the board



Parmod Kumar  
Managing Director  
DIN: 00126965

Place: Ambala  
Dated: 13-02-2025